MET-2

Phase 1Small molecule

NNuBiyota

MET-2 is one of 104 small molecule programs targeting Clostridium Difficile Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clostridium Difficile InfectionActive, not recruiting

Ulcerative ColitisActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Clostridium Difficile InfectionPhase 1

Active, not recruiting

Ulcerative ColitisPhase 1

Active, not recruiting

Generalized Anxiety DisorderPhase 1

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Phase 3

12 2

Velsipity

Pfizer

Phase 3

11 3

Jyseleca

Gilead

Phase 3

6 4

Skyrizi

AbbVie

Phase 3

6 5

Tremfya

Johnson & Johnson

Phase 3

2 6

Orencia

Bristol-Myers Squibb

Phase 3

1 7

Mounjaro

Eli Lilly

Phase 3

1 8

Adtralza

LEO Pharma

Phase 3

1 9

Purinethol

SStason

Phase 3

1 10

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depression1 trial

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression

Unknown status·NNuBiyota·Phase 2·NCT04602715·60 enrolled

Ulcerative Colitis1 trial

Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC)

Completed·NNuBiyota·Phase 1·NCT03832400·11 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of MET-3 in Obese Human Subjects

Completed·NNuBiyota·Phase 1·NCT03660748·15 enrolled

Colonization1 trial

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation

Withdrawn·UUniversity Health Network, Toronto·Phase 2·NCT06214403

Generalized Anxiety Disorder1 trial

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder

Completed·NNuBiyota·Phase 1·NCT04052451·21 enrolled

1 more indication

Clostridium Difficile Infection1 trial

MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

Completed·NNuBiyota·Phase 1·NCT02865616·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for MET-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MET-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MET-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NuBiyota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNuBiyota

MET-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depression1 trial

Ulcerative Colitis1 trial

Safety and Efficacy1 trial

Colonization1 trial

Generalized Anxiety Disorder1 trial

Clostridium Difficile Infection1 trial

References

Drug Info

Quick Facts

Related News